No cases of cervical cancer have been identified during a review into cervical screening tests carried out by the Southern Trust dating back to 2008.
In October last year, the Trust launched a precautionary cervical screening review for 17,543 women.
It came after a highly critical report commissioned by the Royal College of Pathologists found that several cytology staff were “significantly underperforming”, mechanisms to check work were flawed, and action taken my management was inadequate.
The report also found that while a majority of negative results issued by the laboratory were correct, a “significant number” of these would likely have been identified as “potentially abnormal” by other laboratories.
The review was carried out in partnership with the Public Health Agency (PHA) to check that the original result provided was correct.
To avoid any conflict of interest, the Southern Trust laboratory did not participate in review of cytology slides; this was undertaken in Belfast, Western and Northern Trust laboratories.
In an update into the review on Thursday, the Southern Trust said the review is now 99.54% complete and to date no cases of cervical cancer have been identified.
Initial findings of the review confirm that the vast majority of previous smear results are unchanged and have been reconfirmed as normal.
As expected, some low-grade abnormalities (around 300) and a very small number of higher-grade abnormalities (fewer than five) have been found.
Identifying high-grade abnormalities does not mean cancer has been found, rather these are pre-cancerous cell changes that could progress to cancer if left unchecked or untreated.
These women are being followed up by clinical staff with further investigation and management if required.
Dr Stephen Austin, Southern Trust Medical Director, said: “During the period 2008 to 2021, some of our screeners’ performance fell below the recognised standard.
“This was identified and actions were taken to deliver improvement. However, at times, the performance of some screeners did not reach the required standard despite having had additional training and support.
“This was not recognised, and we apologise for this.
Read more
“The Cervical Cytology Review has been a significant undertaking, but it has shown that, for the vast majority of women, their original result did not change.
“However, I am very mindful of the distress this process has caused over recent months and I apologise again to all those women affected.
“The review was carried out in a very comprehensive manner and I must thank laboratory colleagues across Northern Ireland for helping us to complete the work as quickly as possible. Cervical screening saves lives and it is essential that women continue to come forward for their cervical testing when invited to do so.”
Each year in Northern Ireland, around 80 women are diagnosed with cervical cancer and tragically there are approximately 21 deaths.
Data from the NI Cancer Registry show that there is no significant variation in incidence, stage at diagnosis, or deaths from cervical cancer between Health and Social Care Trust areas.
Between 2019 and 2024, there have been 60 confirmed cases of cervical cancer in the Southern Trust area which have been reviewed through the audit process.
All women diagnosed with an invasive cervical cancer between 2019 and June 2024 have had a full cervical screening history review to identify learning to improve the screening programme.
Meetings to discuss audit findings have taken place with those women who had learning identified in their audit outcome.